Introduction – Addressing Core Industry Pain Points
Radiologists and nuclear medicine physicians face a critical challenge: modern imaging devices (PET, SPECT, MRI, CT) generate massive volumes of molecular-level data, but traditional viewing software cannot integrate these modalities or extract quantitative biomarkers. A single PET/CT study produces 500–1,000 images; manually correlating metabolic activity with anatomical structures takes 30–45 minutes and suffers from inter-reader variability. Molecular imaging software solves this through automated image registration, multimodal fusion (PET+MRI+CT), kinetic modeling, and AI-based segmentation—reducing analysis time to 5–10 minutes while providing standardized uptake values (SUV), metabolic tumor volume, and total lesion glycolysis. The core market drivers are precision oncology, theranostics (Lu-177 PSMA, I-131 therapy), and regulatory requirements for quantitative imaging biomarkers in clinical trials.
Global Leading Market Research Publisher QYResearch announces the release of its latest report *”Molecular Imaging Software – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″*. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Molecular Imaging Software market, including market size, share, demand, industry development status, and forecasts for the next few years.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart】
https://www.qyresearch.com/reports/6098023/molecular-imaging-software
Market Sizing & Growth Trajectory (2025–2032)
The global molecular imaging software market was valued at approximately US$ 252 million in 2025 and is projected to reach US$ 363 million by 2032, growing at a CAGR of 5.4% from 2026 to 2032. This relatively modest growth rate reflects market maturity in developed regions (North America, Europe) offset by rapid adoption in Asia-Pacific (China, India, South Korea). Software pricing ranges from $15,000–50,000 per workstation license to $150,000–500,000 for enterprise PACS-integrated solutions.
Keyword Focus 1: Multimodal Fusion – PET/CT to PET/MRI Integration
Multimodal image fusion is the core value proposition of molecular imaging software, combining functional (molecular) and anatomical data:
PET/CT fusion (dominant, ~70% of clinical use):
- Aligns metabolic activity (PET) with anatomical reference (CT)
- Software requirements: rigid and deformable registration algorithms
- Accuracy benchmark: <2mm registration error for head/neck, <5mm for torso
PET/MRI fusion (fastest-growing, +18% YoY in clinical installations):
- Superior soft-tissue contrast for brain, liver, prostate imaging
- Technical challenge: MRI distortion correction (B0 field inhomogeneity)
- Siemens Healthineers’ 2025 “MR-Integrated PET Reconstruction” reduces distortion to <1mm
SPECT/CT and multi-tracer fusion (niche, growing for theranostics):
- Enables dosimetry calculations for Lu-177 and I-131 therapies
- Requires time-activity curve integration across multiple time-point scans
Exclusive observation: A previously overlooked workflow bottleneck is non-rigid registration for abdominal organs (liver, pancreas) that move with respiration and peristalsis. GE HealthCare’s 2025 “MotionFree Fusion” uses respiratory gating and deformable algorithms, reducing liver lesion misregistration from 8mm to 3mm—clinically significant for radioembolization (Y-90) planning.
Keyword Focus 2: Kinetic Modeling – From Static SUV to Dynamic Parameters
Standard SUV (standardized uptake value) is semi-quantitative and affected by scan timing, blood glucose, and patient habitus. Advanced molecular imaging software offers kinetic modeling for true quantitative analysis:
Compartmental modeling (reference standard):
- Estimates rate constants (K1, k2, k3, k4) for tracer influx/efflux
- Requires dynamic scans (60–90 minutes, multiple frames)
- Applications: FDG (glucose metabolism), FLT (proliferation), FMISO (hypoxia)
Patlak graphical analysis (simplified, clinically adopted):
- Estimates net influx rate (Ki) from 20–60 minute post-injection data
- More reproducible than SUV (coefficient of variation 8–12% vs. 15–25%)
- Hermes Medical Solutions’ “PatlakQuant” received FDA clearance in December 2025
Parametric imaging (emerging, +32% vendor investment in 2025):
- Generates voxel-wise parametric maps (e.g., Ki map, DV map)
- Enables heterogeneity analysis (tumor subregions with different kinetics)
- Bruker’s “Parametric Suite” (Q1 2026) generates 7 parametric maps from a single dynamic PET scan
Real-world case: Memorial Sloan Kettering Cancer Center (MSKCC) implemented kinetic modeling software for FDG-PET in lymphoma patients (October 2025). Compared to standard SUV-based response assessment, kinetic parameters predicted treatment failure at 6 weeks (vs. 12 weeks for SUV), enabling earlier therapy change. MSKCC reported 22% reduction in ineffective chemotherapy cycles.
Keyword Focus 3: Precision Medicine – Theranostics & Radiomics
Molecular imaging software is increasingly integrated into precision medicine workflows:
Theranostics (therapy + diagnostics) workflow (fastest-growing application, +28% YoY):
- PSMA-PET for prostate cancer patient selection for Lu-177 therapy
- DOTATATE-PET for neuroendocrine tumors (Lu-177 or Y-90 therapy)
- Software requirements: lesion segmentation (automatic or semi-automatic), dosimetry calculation, response assessment
- GE HealthCare’s “Theranostics Navigator” (released November 2025) reduces dosimetry calculation from 4 hours to 30 minutes
Radiomics and texture analysis (emerging, +40% YoY in research publications):
- Extracts 100–1,000 quantitative features from tumors (shape, intensity, texture)
- Predicts genotype, treatment response, and prognosis
- Technical challenge: feature reproducibility across scanners and reconstruction protocols
- IBSI (Image Biomarker Standardization Initiative) 2025 guidelines improved cross-scanner reproducibility from R²=0.65 to R²=0.85
AI-based segmentation (adopted by 45% of academic centers, 15% of community hospitals):
- Automatic tumor delineation (3D U-Net, nnU-Net architectures)
- Reduces segmentation time from 15 minutes (manual) to 30 seconds (AI)
- FDA-cleared AI segmentation (Siemens AI-Rad Companion) available since Q1 2025
Recent Industry Data & Regulatory Updates (Last 6 Months – October 2025 to March 2026)
- FDA’s “Quantitative Imaging Biomarker Alliance” (QIBA) profile for FDG-PET (January 2026): Mandates software compliance with SUV harmonization standards (EANM/EARL or similar) for multi-center clinical trials. Non-compliant software cannot be used in FDA-regulated drug trials. Impact: 6 smaller software vendors lost clinical trial business.
- EMA’s guideline on image-based patient selection for radioligand therapy (December 2025): Requires lesion-level dosimetry (not just SUV) for Lu-177 PSMA therapy planning. Hermes Medical Solutions and GE HealthCare gained market share; vendors without dosimetry modules (including Carestream, Inter Medical) face obsolescence in theranostics.
- China’s NMPA “AI Medical Software Classification Guideline” (updated February 2026): Classifies AI-based lesion segmentation as Class III (highest risk) software requiring clinical trials. Approval timeline: 12–18 months (vs. 6–9 months for non-AI software). This favors established vendors (Siemens, GE, Bruker) over AI startups.
Technology Deep Dive & Implementation Hurdles
Three persistent technical challenges remain:
- Cross-scanner harmonization: PET and MRI reconstruction algorithms vary by vendor, affecting quantitative values (SUV can vary ±15–20% between scanners). Software must include calibration factors or harmonization algorithms. Solutions: EANR/EARL accreditation (adds $10,000–20,000 per site); manufacturer-specific plugins (GE’s “Q.Clear”, Siemens “HD·PET”).
- Motion correction in long dynamic scans: 60–90 minute dynamic PET scans are affected by patient movement (respiratory, cardiac, bulk motion). Software must include motion detection and correction. Convergent Imaging Solutions’ 2025 “MotionTrace” uses optical surface tracking, reducing motion artifacts by 78%.
- Computational performance for parametric imaging: Voxel-wise kinetic modeling requires 10–100× more computation than SUV. A whole-body dynamic PET (150 time frames, 200×200×200 voxels) requires 1–2 hours on standard workstations. GPU acceleration (NVIDIA Clara, 2025) reduces to 8–12 minutes.
Discrete vs. Continuous Processing – A Software Industry Insight Often Overlooked
Medical imaging software differs fundamentally from industrial or continuous-process software:
- Discrete event processing: Each patient study is an independent discrete event. Unlike continuous monitoring systems (power grid, refinery control), molecular imaging software cannot assume steady-state conditions—each scan has unique tracer kinetics, patient anatomy, and motion patterns. This requires adaptive algorithms, increasing development complexity.
- Regulatory update cycles: Software as a Medical Device (SaMD) requires FDA/CE re-approval for major updates (6–12 months). Continuous delivery (typical in enterprise SaaS) is impossible. Siemens Healthineers maintains 3 release cycles per year (vs. 50+ for non-medical SaaS), limiting feature velocity.
- Interoperability burden: Must integrate with PACS (DICOM), RIS (HL7), and EMR (FHIR). DICOM Supplement 222 (PET/MRI fusion) was only finalized in October 2025—20 years after PET/CT became clinical standard. This slow standardization benefits incumbents (GE, Siemens) and challenges startups.
Exclusive analyst observation: The most successful molecular imaging software vendors have adopted modular architecture with containerized deployment—separate modules for registration, segmentation, kinetic modeling, and reporting, deployed via Docker/Kubernetes. This allows faster updates (FDA-classified as “minor changes” for non-AI modules) while maintaining regulatory compliance. Bruker’s 2025 architecture reduced update approval time from 8 months to 3 months for non-AI modules.
Market Segmentation & Key Players
Segment by Type (software modality focus):
- Nuclear Medicine Molecular Imaging Software (PET, SPECT): 55% of revenue, largest segment
- Multimodal Fusion Software (PET/CT, PET/MRI, SPECT/CT): 28% of revenue, fastest growing (CAGR 7.2%)
- Optical Molecular Imaging Software (fluorescence, bioluminescence): 10% of revenue, primarily preclinical
- Others (ultrasound molecular imaging, photoacoustic): 7% of revenue, emerging
Segment by Application:
- Precision Oncology Diagnosis and Treatment: 45% of revenue, largest application (theranostics, response assessment)
- Drug Development (preclinical and clinical trials): 25% of revenue, stable growth
- Neuroscience Research (neurodegenerative diseases, psychiatry): 15% of revenue
- Cardiovascular Disease Assessment (perfusion, viability, inflammation): 10% of revenue
- Others (infectious disease, immunology, gene therapy): 5% of revenue
Key Market Players (as per full report): Bruker, Carestream, Convergent Imaging Solutions, Cytiva, GE HealthCare, Hermes Medical Solutions, Inter Medical, KODAK, MR Solutions, Siemens Healthineers.
Conclusion – Strategic Implications for Healthcare Providers & Software Vendors
The molecular imaging software market is growing at 5.4% CAGR, with precision oncology (theranostics) and drug development as primary growth engines. Multimodal fusion (especially PET/MRI) and kinetic modeling are replacing static SUV as standard-of-care in leading academic centers. For healthcare providers, investment in AI-based segmentation and dosimetry modules is essential for theranostics programs. For software vendors, differentiation lies in cross-scanner harmonization, motion correction, and regulatory compliance (QIBA, EMA dosimetry guidelines). The next three years will see consolidation as large vendors (GE, Siemens) acquire AI startups, while smaller players (Hermes, Convergent) focus on niche applications (theranostics dosimetry, neuroscience). The transition from perpetual licenses (workstation-based) to cloud-based subscription models will accelerate, driven by multi-site enterprise customers and AI compute requirements.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
